Axovant Sciences Ltd. IPO Info
Company Name: Axovant Sciences Ltd.
Stock Symbol: AXON
Exchange: NYSE
Status: Priced
IPO Date: 6/11/2015
IPO Price:
15.00 (
20.20%)
Underwriters
Jefferies, Evercore, RBC, JMP, Baird
Amount of Offering: N/A
Number of Shares Offered: 17.9 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
We are a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Our goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. Our near-term focus is to develop our product candidate, which we refer to as RVT-101, for the treatment of Alzheimer's disease and other forms of dementia. We acquired worldwide rights to RVT-101 from Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited, collectively GSK, in December 2014. We plan to commence a Phase 3 pivotal program of RVT-101 for the treatment of mild-to-moderate Alzheimer's disease in the fourth quarter of 2015. If our Phase 3 program is successful, we plan to seek regulatory approval and commercialize RVT-101 in the United States and the European Union. In the long-term, we intend to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia.
News Headlines
